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The effect of a superinfection with bluetongue virus serotype 1 (BTV1) was evaluated on two groups 36 
of four calves. One group received a commercial inactivated BTV serotype 8 (BTV8) vaccine. This 37 
group and the non-vaccinated group of calves were challenged twice (4 months apart) with the 38 
European BTV8 strain isolated during the 2006-2007 epidemics. Calves were then infected with a 39 
BTV1 inoculum which was found to be unexpectedly contaminated by BTV serotype 15 (BTV15). 40 
BTV1 and BTV15 single infections were performed on two other groups of three BTV naïve calves.   41 
A severe clinical picture was obtained after superinfection with BTV1/BTV15 in both vaccinated and 42 
non-vaccinated animals and after challenge with BTV8 in non-vaccinated animals. BTV1 and BTV15 43 
single infection caused only very slight clinical signs. 44 
After superinfection and at the viraemic peak, there were an average of above 1000 times more 45 
BTV15 genomic copies than BTV1 ones. BTV1 RNA could be detected only in the spleen of one calf 46 
whereas BTV15 RNA was found in 15 organs of 7 different animals. BTV8 immunization whether it 47 
was acquired through vaccination and challenges or challenges alone did not change BTV1 or BTV15 48 
RNA detection in superinfected animals. However in these animals a partial cross neutralization 49 
between BTV8 and BTV1 might be involved in the lower BTV1 replication versus BTV15.   50 
Infection with different serotypes can occur also in the field. Interference between virus strains, 51 
genetic reassortment and cross-protection were considered as mechanisms to explain the clinical 52 
outcomes and the other virological and immunological findings in the course of BTV1/BTV15 53 
superinfection.  54 
 55 





Bluetongue (BT) is a non-contagious disease affecting ruminants and is caused by the bluetongue 59 
virus (BTV), the type species of the genus Orbivirus. BT is a World Organization for Animal Health 60 
reportable disease and is of considerable socioeconomic concern and of major importance in the 61 
international trade of animals and animal products [1]. Economic losses associated with BTV infection 62 
are caused directly through reductions in animal productivity and death, implementation of control 63 
measures, and more importantly, indirectly through trade losses due to animal movement restrictions 64 
[2]. 65 
Within each different Orbivirus species, several virus serotypes are identified, based on the specificity 66 
of reactions with the neutralizing antibodies generated by their mammalian host [3]. These reactions 67 
are dependent to a large extent to VP2 and also VP5, which are the most variable proteins in BTV; 68 
VP2 especially contains the most epitopes that drive neutralizing antibodies production and therefore 69 
is the main determinant of the serotype [4]. To date, 27 serotypes have been identified, including 70 
BTV25 identified in Switzerland in 2007 [5], BTV26 from Kuwait in 2010 [6] and BTV27 detected in 71 
goats in Corsica (France) in 2014 [7]. In addition, two putative new serotypes, respectively BTV28 72 
and BTV29 were recently detected [8]. Indeed serological cross-reactions between different serotypes 73 
are described [9] and evidences of possible heterologous cross-protection do exist [10, 11], but their 74 
influence on the epidemiology of the disease is not sufficiently understood.  75 
From 2006 to 2015, seven BTV serotypes were detected in Western and Central Europe, namely 76 
BTV1, 6, 8, 11, 14, 25, and 27. Most of the economic losses have to be attributed to BTV8, and to a 77 
lesser extent, BTV1, with respectively over 27000 and 6000 holdings affected only in 2008. BTV8 78 
alone was responsible for the death of more than 20000 sheep in Belgium, which represents 5-10 % of 79 
the national flock [12]. The 2008 BTV8 epizootic in Northern Europe is believed to have caused 80 
greater economic damage than any previous single serotype BT outbreak [13]. By contrast re-81 
emergence of BTV8 in France in 2015 was only of limited impact [14]. 82 
On the other hand, BTV1 that circulated contemporarily in Southwest Europe, was described as a 83 
virus leading to subclinical or mild disease in cattle [15]. As a consequence of this epidemiologic 84 
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context, domestic ruminants in the field could be sequentially infected by these two serotypes, as it 85 
was reported in France and Spain [16].  86 
In this paper the results of a 9 month-long experiment are shown. Calves were originally divided in 87 
two groups, with one group being vaccinated against BTV8, and were subsequently both challenged 88 
with a homologous BTV8 European strain. In order to mimic the occurrence of repetitive infections 89 
according to studies reporting several peaks of vector activity during the course of the year [17], the 90 
same calves were infected a second time with the same BTV8 strain and later with BTV serotype 1 91 
(BTV1) (superinfection). The aim of this study was to analyse the outcome of these successive 92 
challenges, taking into account the influence of vaccine immunity as well as natural post-infection 93 
immunity. The BTV1 inoculum appeared to be contaminated with BTV15 [18]. In order to evaluate 94 
any in vivo cross-protection, the consequences of a BTV1 and BTV15 single infection in BTV naïve 95 
calves were also considered.  96 
Materials & methods 97 
BTV8 successive infections  98 
Ten Holstein female calves, about 6-7 months old, were used. All the animals were tested seronegative 99 
and non viraemic for BTV and bovine viral diarrhoea virus (BVDV), and seronegative for bovine 100 
herpesvirus 1 (BoHV1). A thorough general clinical examination was carried out on all the animals by 101 
a veterinarian before including them in the study, to confirm their asymptomatic state, in accordance to 102 
physiological standards [19].  103 
The calves were housed in an insect-secured BSL3 zone at the Experimental Infectiology Platform 104 
(PFIE) of the INRA centre of Tours (Nouzilly, France). The local ethical committee approved the 105 
experimental protocol (dossier n.2011-10-1). Three groups were created: a group of four non-106 
vaccinated calves (group NV, calves 1-4), a group with four vaccinated calves (group V, calves 5-8), 107 
and an environmental control group with two calves (group C, calves 15 and 16). Vaccination against 108 
BTV8 was performed using the inactivated commercial vaccine BTVPUR AlSAP 8 (Merial, Lyon, 109 
France) following manufacturer’s instructions.  110 
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Calves of group V and NV were infected twice, four months apart, using the same BTV8 inoculum 111 
described in a previous experimental infection [20]. Briefly, a calf inoculated with a BTV-8 strain 112 
passaged twice in baby hamster kidney fibroblasts (BHK-21) cells (BEL2006/01 BHK-21 P2), was 113 
blood sampled at the viraemic peak, showing clinical signs. The first infection took place 50 days after 114 
the second vaccine shot, and the second challenge 120 days later (Figure 1A). Each time, half of the 115 
dose was inoculated via the jugular vein and half subcutaneously. For each one of these challenges, all 116 
8 infected animals were administered a total of 15 ml of blood, corresponding to a titre of 10
3 
embryo 117 
lethal dose 50 (ELD50).  118 
The animals were daily examined and sampled for EDTA-blood and whole blood on dry tubes during 119 
the 3 first weeks after infection, then twice a week until superinfection. For clarification purpose, days 120 
post infection regarding BTV8 successive infection are mentioned as dpiBTV8, with day of first 121 
challenge as dpiBTV8 0. 122 
BTV superinfection 123 
About 5 months (160 days) after the first BTV8 infection, and 40 days after the second one, calves of 124 
groups NV and V were challenged with BTV1 infectious blood, kindly provided by the Friedrich-125 
Loeffler Institute. Each animal received 10
6.15 
tissue culture infective dose 50% (TCID50) of virus, half 126 
intravenously and half subcutaneously. An incidental contamination of the inoculum with BTV15 was 127 
discovered during the course of the study [18].  128 
The animals were daily examined and sampled for EDTA-blood and whole blood on dry tubes until 129 
the end of the experiment.  130 
Calves were euthanized 21 days after the superinfection and necropsied (Figure 1A-B). Days post 131 
infection for superinfection is mentioned as dpiBTV1/15. 132 
BTV1 and BTV15 single infections 133 
Eight Holstein male calves, about 6-7 months old, were housed in the BSL3 facility, at CODA-134 
CERVA’s (Veterinary and Agrochemical Research Centre, Uccle, Belgium) experimental centre 135 
(Machelen, Belgium). These animals fulfilled the same inclusion criteria of the BTV8 successive 136 
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infections and were naïve for BTV, BVDV and BoHV-1. The experimental protocol was reviewed by 137 
the competent authority (Ethical Committee of the Institute of Public Health-Veterinary and 138 
Agronomical Research Centre) and subsequently approved (ref. 110228-01 RT 10/10 139 
BLUETONGUE). 140 
After an acclimatization period of two weeks, calves were divided in three groups (BTV1: calves 9-11, 141 
and BTV15: calves 12-14, single infections; mock-infection: four calves (calves 17-20)).  The 142 
infection was performed with a volume of 1 ml of virus diluted in Dulbecco's Modified Eagle Medium 143 
(DMEM, Lonza BioResearch, Belgium), half intravenously and half subcutaneously.   144 
The BTV1 strain has been provided by CODA-CERVA, from sub-saharian origin, derived from the 145 
European Community Reference Laboratory for bluetongue at the Pirbright Laboratory, United-146 
Kingdom) collections, and subsequently passaged 2 times in BHK-21cells. The infection was 147 
performed with 10
6 
TCID50 per animal.  148 
BTV15 was provided by CODA-CERVA, derived from the European Community Reference 149 
Laboratory for bluetongue at the Pirbright Laboratory, United Kingdom) and was then passaged twice 150 
on BHK21 cells at CODA-CERVA. Calves were infected with 10
4 
TCID50.  151 
Mock-infected calves were inoculated with sterile DMEM following the same routes and volume.  152 
The animals were daily examined and sampled for EDTA-blood and whole blood on dry tubes until 153 
the end of the experiment. Calves were euthanized 35 dpi and necropsied. Days post infection for 154 
single infections are mentioned as dpisingle. 155 
Clinical and post-mortem examination 156 
After each challenge, the individual body temperature and the clinical signs were monitored for three 157 
weeks. The severity of the infection was quantified by calculating clinical scores on a daily basis, 158 
leading to overall cumulative clinical scores by groups and animal. For this purpose, a standardised 159 
clinical form adapted from Saegerman et al. was used [21]. As BTV1 and BTV15 single infections 160 
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only involved 3 animals whereas other groups had 4 calves each, total clinical score was pondered to 161 
allow direct comparison of clinical scores from different experiments.  162 
Samples of spleen, thymus, prescapular and mesenteric lymph nodes were collected from infected and 163 
control calves and stored at −80 °C for virus detection.  164 
Serology 165 
Neutralizing antibodies (Abs) were titrated by seroneutralization (SNT). Two-fold serial dilutions of 166 
the sera (1:10-1:1280) were tested in the presence of 100 TCID50 of virus, as previously described 167 
[22]. The neutralizing antibody titre was defined as the reciprocal of the serum dilution causing a 50% 168 
reduction in cytopathic effect. Serum samples with a titre <20, =20 and >20 were considered negative, 169 
doubtful and positive, respectively. 170 
In order to identify in vitro cross neutralization between BTV1, BTV8 and BTV15, the serum of the 171 
calf infected with BTV8 and showing the highest anti-BTV8 antibody titre was tested in the presence 172 
of BTV1 or BTV15. Similarly, the serum of the calves infected with BTV1 and BTV15 following 173 
single serotype infections and showing the highest neutralizing antibody titres against the 174 
correspondent virus were tested against heterologous serotypes. In vitro cross neutralization was 175 
measured using the percentage of neutralization obtained using heterologous serotypes with immune 176 
serum and compared to homologous neutralization as reference (100 %).     177 
In the course of the two BTV8 challenges, and after BTV1 and BTV15 single infections, 178 
seroconversion against VP7 antibodies was also evaluated using a commercial competitive ELISA kit 179 
(ID Screen® Bluetongue Competition ELISA kit, ID Vet, France). Results were expressed as % of 180 
negativity (PN) compared to the negative kit control and transferred to a positive, doubtful or negative 181 
result according to the cut-off settings provided by the manufacturer (PN ≤ 35 is positive; 182 
35 < PN ≤ 45 is doubtful; PN > 45 is negative). 183 
BTV RNA detection 184 
Viral RNA extraction from the blood was achieved using the QIAamp Viral RNA Mini Kit (Qiagen, 185 
Germany). Viral RNA denaturation and reverse transcription followed by qPCR were performed as 186 
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previously described [23]. BTV RNA was detected by serotype specific RTqPCR, using a fragment of 187 
BTV segment 2 as the target. Serial dilutions of in vitro constructed plasmids (pGEM®-T Easy 188 
Vector, Promega, The Netherlands) carrying the target part of the segment 2, specific for each 189 
serotype, allowed the absolute quantification of the viral cDNA equivalent in samples. Quantification 190 
was expressed in cDNA copy number/ml of blood.  RTqPCR cycling conditions, primers and probes 191 
were similar to the ones described by Vandenbussche et al. (2009) for BTV1 and BTV8 192 
(RTqPCR_BTV1_S2 and RTqPCR_BTV8_S2, respectively), and Eschbaumer and al. (2011) for 193 
BTV15 (RTqPCR_BTV15_S2). In all the RTqPCR of this study, bovine beta-actin was 194 
contemporaneously amplified as internal control (RTqPCR_ACT) [24].  195 
BTV RNA detection was performed on all the collected organs starting from approximately 100 mg of 196 
tissue, which was processed using TRI reagent according to the manufacturer’s instructions (Life 197 
Technologies Europe BV, Gent, Belgium). BTV and bovine beta-actin detection were performed by 198 
RTqPCR as described above. 199 
Viral growth assay 200 
In vitro replication of BTV1, BTV8 and BTV15 were compared on VERO and Bovine Pulmonary 201 
Endothelial cells (BPAEC). BTV8 was the same as in the BTV8 successive infections, and BTV1 and 202 
BTV15 were the same as in single infections. These viruses were used for a growth assay following a 203 
protocol previously described [25]. Briefly, VERO and BPAEC confluent cells in 24 wells plates were 204 
inoculated with a multiplicity of infection (M.O.I.) of 0.05, and after 0, 8, 24, 48 and 120 hours post 205 
infection (hpi), supernatant was removed and stored at -80°C. Each virus underwent three independent 206 
assays on each cell type. Supernatants were then titrated by end-point dilution and titres expressed as 207 
Log10 of TCID50/ml.  208 
Statistical analysis 209 
Mean cumulative clinical scores were analysed using linear mixed model, with calf as random effect. 210 
Viraemia and serological results were compared using two-way ANOVA with repeated measures. 211 
RNA detection in organs at necropsy, frequencies and proportions were compared with Fisher's Exact 212 
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Test for count data [26]. For all tests, P values < 0.05 were considered significant. In case of multiple 213 
comparisons, a Bonferroni correction was applied to reduce the risk of type I error (conservative 214 
approach) and a Holm correction was applied when more than 4 comparisons had to be tested. 215 
Statistical analyses were performed using the R software/environment (R-3.1.2, R Foundation for 216 
Statistical Computing, http://www.r-project.org/) and SAS software, Version 9.3 TS level 1M2 of the 217 
SAS System for Unix, and SAS University Edition (SAS Institute, Cary, NC).  218 
Results 219 
BTV8 successive infections  220 
Clinical examination 221 
From the beginning to the end of the experiment, control calves and vaccinated animals (V) did not 222 
show any clinical signs that could be related to BTV infection. After the first challenge, clinical signs 223 
showed by NV calves were slight, mostly consisting in ocular lesions and to a lesser extent by oral 224 
lesions. Clinical signs consistent with BTV8 infection could be reported from 7 to 21 dpiBTV8. After 225 
the second challenge no clinical manifestations or temperature rise could be detected in any animal.  226 
Serology 227 
VP7 and anti-BTV8 neutralizing Abs in control calves could not be detected at any tested time points. 228 
First vaccination of the calves did not induce detectable neutralizing Abs, which could only be 229 
detected 7 days after the booster vaccination. In NV group, neutralizing Abs were first detected at 18 230 
dpiBTV8 (Figure 1A). The titre of anti-BTV8 neutralizing Abs of the V group was significantly higher 231 
between -43 dpiBTV8 (thus 35 days after the first vaccine shot) and 27 dpiBTV8 (P<0.005), and then Abs 232 
titres of both NV and V groups followed a similar trend until the end of the experiment (Figure 1A).   233 
Following the second BTV8 challenge, neutralizing Abs titres underwent a boost in both NV and V 234 
groups until 33 dpiBTV8 (Figure 1A).  235 
The use of an ELISA allowed the detection of anti-VP7 Abs in all the vaccinated animals as soon as 3 236 
days after second vaccine injection (Figure 2). Then PN of vaccinated animals did not evolve 237 
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significantly until the end of the measures at 180 dpiBTV8 (additional file 1). Non-vaccinated calves 238 
were confirmed seropositive between 10 and 19 dpiBTV8, with no significant variations until the end of 239 
the measures at 180 dpiBTV8 (additional file 1, P > 0.05). 240 
BTV RNA detection 241 
BTV8 RNA was never detected in the EDTA-blood samples of control and vaccinated calves during 242 
the course of the two BTV8 infections. In the NV group of calves, BTV RNA could be detected 243 
starting from 5 dpiBTV8. After the viraemic peak (11-15 dpiBTV8) a progressive decrease in BTV8 RNA 244 
was measured (Figure 1A-B), until the end of the experiment.  245 
BTV superinfection 246 
Clinical and post-mortem examination 247 
In the NV as well as in the V group, lesions following BTV1/BTV15 superinfection were mainly 248 
conjunctivitis with serous to purulent discharge. Erosions of the muzzle, erosions and ulcerations of 249 
the gums and the dental pad and later crusts on the muffle or on the cutaneous-mucous junction were 250 
commonly notified. Reddening and swelling of the coronal margin and interdigital space were also 251 
mentioned. Conjunctivitis and congestion of the lower limb were mild to severe and respectively less 252 
severe and absent in the previous BTV8 infection. At the end of the experiment cumulative clinical 253 
score of the NV BTV1/BTV15 superinfected group was higher than in NV BTV8 and V 254 
BTV1/BTV15 groups, however the difference was not significant (P>0.4, additional file 2).   255 
The necropsy revealed petechial haemorrhages of limited extent in prescapular and submandibular 256 
lymph nodes, and thymus, at least in one of these organs in all the superinfected calves. BTV8 RNA 257 
could be detected in prescapular lymph node of one calf and in the spleen of another one, both from 258 
NV group; BTV1 RNA could only be detected in the spleen of one vaccinated calf and BTV15 RNA 259 
could be detected with a significant higher frequency (P<10
-5
) in 15 organs belonging to 7 different 260 
calves (5/15 in NV group and 10/15 in V group; Figure 3).  261 




After the superinfection, high levels of residual neutralizing antibodies against BTV8 were found 264 
throughout the experiment in all the infected animals, with a roughly steady level (Figure 1A and B). 265 
There were no significant differences between NV and V groups through time in anti BTV8 266 
neutralizing antibodies (two-way ANOVA with repeated measures, group effect: P=0.78, group time 267 
interaction: P=0.84). By contrast, BTV1 only gave rise to very low titres of neutralizing antibodies.  268 
BTV15 neutralizing antibody titre increased regularly after infection, with a positive titre detectable in 269 
most of the animals at 9 dpiBTV1/15 (Figure 1B). BTV15 neutralizing Abs followed an increasing trend 270 
until the time of euthanasia; in previously vaccinated animals a higher and significant earlier raise of 271 
neutralizing antibody was found compared to non-vaccinated ones (two-way ANOVA with repeated 272 
measures, group effect: P<0.02, group time interaction: P<2X10
-4
) (Figure 1B). 273 
BTV RNA detection 274 
At the time of the superinfection, a residual BTV8 RNAemia was detected in the NV group of calves. 275 
BTV8 RNAemia decreased through the time of the experiment, but was still detectable in all the NV 276 
animals by the time of euthanasia (180 days after the first BTV8 challenge – Figure 1).  277 




copies of segment 2 cDNA per ml 278 
of blood, for BTV1 and BTV15.  279 
After superinfection in the NV and the V groups, BTV1 could only be detected inconstantly, from one 280 
to 3 days amongst all the tested day-points and at lower copy number than BTV15 (Figure 1B). On the 281 
contrary, BTV15 could be easily detected in both groups and among all the infected calves. RNAemia 282 
through time was significantly different between BTV15 and BTV1 whichever the considered 283 
vaccination status of the animals (P<10
-8
). Mean copy number at viraemic peak was 10
5.4
 (+/- 0.7 Log) 284 
cDNA copy number / ml of blood for BTV15 and 10
2.4
 (+/- 1.8 Log) for BTV1. BTV15 could be 285 
detected until the end of the experiment (Figure 1B). Between V and NV groups, detection of BTV1 286 
and BTV15 was not significantly different (P=0.18 and P=0.86 for BTV1 and BTV15 respectively). 287 
No viral RNA could be detected in control animals (data not shown). 288 
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BTV1 and BTV15 single infections 289 
Clinical and post-mortem examination 290 
During BTV1 single infection, one calf underwent sporadic hyperthermia and all the three calves of 291 
the group had mild oral and ocular lesions. No systemic impact was reported in any of these animals.  292 
During BTV15 single infection, infected animals showed very mild clinical conditions compatible 293 
with BT, including congestion and crusts on the nostrils and oral mucosa. One calf showed 294 
hyperthermia at 7 dpi (39.6°C) and at 14 (40°C) and 15 dpi (40.7°C), with no other lesion throughout 295 
the experiment (additional file 2). No hyperthermia was recorded in any of the other cattle at any stage 296 
of the experiment.  297 
Overall, the sum of clinical scores in BTV1 and BTV15 single infected groups were not significantly 298 
different when compared to control animals or to the V group after BTV8 challenge (P>0.14), but 299 
were significantly lower when compared to first BTV8 challenge in NV calves and the superinfection 300 
with BTV1/15 inoculum in both V and NV groups (P<0.002). 301 
Necropsy for BTV1 single infection revealed moderate petechial haemorrhages in mesenteric and 302 
mediastinic lymph nodes in one calf, prescapular and mediastinic lymph nodes in another one and no 303 
lesions in the last one. 304 
In the calves with BTV15 single infection, no BTV specific lesions could be found at necropsy. 305 
Petechial haemorrhages were reported on the thymus and the prescapular lymph node of two calves, 306 
respectively, in both cases on a limited amount. 307 
All the three BTV1 infected calves had a positive BTV1 detection in prescapular lymph nodes. In 308 
addition, viral RNA could be detected in the thymus and spleen of two other calves, respectively 309 
(Figure 3). 310 
RTqPCR revealed BTV15 positive detection in the spleen and the prescapular lymph nodes of all of 311 
the three BTV15 infected calves. In addition, thymus and mesenteric lymph node were shown to be 312 
positive in two calves, respectively (Figure 3). The frequency of positive detection in organs was not 313 
different between BTV1 and BTV15 (Fisher's Exact Test for count data, P>0.4). 314 
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No specific lesions or BTV RNA detection could be found in control animals.  A few non-specific 315 
abscesses could be found in the lung of one of these calves. 316 
Serology 317 
During BTV1 single infection anti-BTV1 neutralizing antibodies could be detected for the first time at 318 
the 16 dpisingle tested time point and then increased regularly until the end of the experiment (Figure 319 
2A). Similarly, also anti-BTV15 neutralizing antibodies were measured starting from 16 dpisingle in the 320 
course of BTV15 single infection and the titres increased regularly until the time of euthanasia (Figure 321 
2A). 322 
There was no significant difference between SNT titres of BTV1 and  BTV15 single infection and 323 
BTV8 after first infection in NV group during the first 35 days (P>0.24). 324 
BTV1 infected calves seroconverted regarding anti-VP7 antibodies between 7 and 16 dpisingle, and 325 
were still all seropositive at the end of the experiment. 326 
Anti-VP7 Abs in BTV15 infected animals clearly increased between 10 and 15 dpisingle in all infected 327 
calves (Figure 2B). However, only 1/3 calves seroconverted at the end of the experiment at 35 dpisingle, 328 
whereas the two other calves remained slightly out the positivity limit (mean PN =38+/- 5.7, Figure 329 
2B). At 35 dpisingle PN of BTV15 infected group was significantly higher when compared to BTV1 330 
single infection group and BTV8 groups at 35 dpiBTV8 (P<0.007). 331 
In vitro cross neutralization assay only showed limited cross reactivity between BTV8 immune serum 332 
against BTV1 virus (18 % +/- 7.4 % of the BTV8 immune serum homologous neutralization, Figure 333 
2C). However, this cross reactivity was significantly higher than the one measured between BTV1 334 
versus BTV15 immune serum, BTV8 versus BTV1 and BTV15 immune serums (P<0.02). BTV1 and 335 
BTV8 immune serum elicited a limited cross reactivity toward BTV15 (10 % +/- 4.5 % and 10 % +/- 336 
1.8 %, respectively). 337 
BTV RNA detection 338 
In the course of BTV1 single infection BTV RNA could be detected as soon as 1 dpi in all the calves 339 
of the group, but then could only be detected again at 2 and 3 dpi for respectively 1 and 2 calves. 340 
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During BTV15 single infection viral RNA could be detected starting from 7 dpi in all three calves. 341 
BTV15 RNA could be detected until the end of the experiment (Figure 2A). The levels of RNA 342 
peaked in the blood of both BTV1 and BTV15 groups between 9 and 11 dpisingle. BTV1 cDNA copy 343 
number detected in single infected calves was significantly higher than in BTV1 superinfected ones, 344 
no matter their vaccination status (P< 10
-4
). By contrast, there were no significant differences in cDNA 345 
copy numbers between BTV15 superinfected (V and NV groups), BTV1 and BTV15 single infected 346 
calves (P> 0.2). Moreover, BTV1 and BTV15 cDNA copy numbers were not significantly different 347 
from BTV8 cDNA copy number during first infection in NV group (P>0.13). 348 
 349 
Viral growth assay 350 
From 0 to 24-48 hpi, BTV1 showed a faster replication, however not significant, whichever the 351 
considered cell line (Figure 4). In VERO cells BTV15 grew less efficiently than BTV1 from 0 to 48 352 
hpi (P<10
-5
), but finally reached by 120 hpi similar titres to BTV1 and BTV8 in VERO cells (P>0.14) 353 
and to BTV1 in BPAEC (P>0.9). Homologous viral growth was not significantly different between 354 
cell types (P=0.15), and there was no significant differences between serotypes in BPAEC (P>0.3).  355 
Discussion 356 
The influence of the existent active immunity towards the European BTV8 strain on the outcomes of a 357 
superinfection with BTV1 was evaluated. The BTV1 inoculum appeared to be contaminated with 358 
BTV15 thus the animals were actually infected with a mixed BTV1-BTV15 inoculum. BTV8 active 359 
immunity was evaluated either by vaccination followed by infectious challenges or by infectious 360 
challenges alone Two successive infections with the same BTV8 strain were realized 4 months apart. 361 
In line with field data [9], vaccination only elicited the production of neutralizing Abs detectable after 362 
the second vaccine boost. Vaccinated animals underwent a significantly earlier detection of 363 
neutralizing antibodies after the first BTV8 challenge when compared to non-vaccinated calves. In the 364 
NV BTV8 group, the detection of BTV8 RNA lasted until 180 dpiBTV8 (end of the experiment), which 365 
is consistent with currently existing literature data [27, 28]. Non-vaccinated calves infected with 366 
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BTV8 showed a slight to mild clinical picture. A moderate impact of the disease caused by BTV8 on 367 
cattle is not unusual, in experimental infections [22, 29] as well as in the field [30-32]. 368 
After the unexpected contamination of the BTV1 inoculum with BTV15, the influence of both viruses 369 
on the outcome of the infection was investigated. In the inoculum used for the superinfection, the copy 370 
number of BTV1 segment 2 cDNA per ml of inoculum was about 10 fold lower than BTV15. After 371 
superinfection BTV1 could be found irregularly and only at a few tested time-points in the blood of 372 
the calves while BTV15 was detected with high levels of RNAemia until the end of the experiment in 373 
both V and NV groups. The overwhelming replication of BTV15 versus BTV1 is in line with results 374 
reported by Eschbaumer et al., (2011). Domination of one serotype on another during mixed infection 375 
has been previously reported [33] and the same authors observed that about 5 % of progeny viruses 376 
were actually reassortants. Any genome segment can be involved in reassortment which is readily 377 
generated, as demonstrated by Shaw et al. [34]. As in the current study viral RNA was based on 378 
segment 2 quantification, it is not possible to rule out that some of the segment 2 detected by RTqPCR 379 
being actually part of reassortant viruses. This was also one of the hypotheses brought to light by Dal 380 
Pozzo et al. (2013) to explain the predominance of BTV8 on BTV1 and BTV15 in the course of a 381 
triple co-infection. Another possible explanation is the viral interference, occuring between two or 382 
more viruses infecting simultaneously the same host.  383 
BTV8 was recently used to study underlying IFN-I control mechanisms by the virus [35]. To 384 
investigate whether the different tested serotypes would also show different replication patterns in 385 
vitro or not, growth curves of BTV1, BTV8 and BTV15 were established in two common cell lines, 386 
BPAEC and VERO cells. VERO cells are deficient for IFN-I production [36]. BTV15 did not replicate 387 
as much as BTV1 in VERO cells during the first 48 hours. Nevertheless, in IFN-I competent cells such 388 
as BPAEC primary line, both BTV serotypes replicated following a similar pattern through time. 389 
These results are not inconsistent with the hypothesis of BTV15 to be better adapted to IFN-induced 390 
state when compared to BTV1, possibly explaining the relatively more efficient replication of BTV15 391 
in vivo or in vitro in IFN-competent cell lines. Another hypothesis to explain the difference between 392 
BTV1 and BTV15 RNAemia after superinfection might be related to the influence of BTV8 immunity 393 
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on these two serotypes. The level of heterologous reactivity as assessed by SNT between BTV8 394 
immune serum and BTV serotypes 1 and 15 was low, yet higher for BTV1 (18+/- 7.4 % versus 10 +/- 395 
1.8 % for BTV1 and BTV15, respectively; Fig. 2 C). This result is in line with Hund et al. (2012), 396 
which reported partial cross neutralization between BTV8 positive serum and BTV1, despite the 397 
genetic distance between these serotypes [9].  398 
In addition, no significant difference was reported between RNAemia of BTV15 superinfected calves 399 
(from V and NV groups, both immunized against BTV8) and RNAemia of BTV15 single infected 400 
calves. Thus this low in vitro humoral cross reactivity between BTV8 immune serum and BTV15 401 
seemed to have no significant influence on BTV15 RNAemia in vivo in contrast to the BTV1 402 
RNAemia.  403 
BTV1/BTV15 superinfection led to clinical disease in both V and NV animals. On the contrary, 404 
during BTV1 and BTV15 single infection the calves had very low clinical scores. The reason of this 405 
difference remains uncertain; however individual variability could be part of the explanation.  406 
After superinfection, BTV1 neutralizing Abs only reached very low levels, as a consequence of the 407 
very low BTV1 RNA detection. By contrast, BTV15 neutralizing Abs extended to high titres, either in 408 
BTV1/BTV15 superinfected animals or in BTV15 single serotype infected calves.  409 
Despite high neutralizing Abs detection following BTV15 single serotype infection, ELISA detecting 410 
VP7 Abs showed a mean PN at 35 dpi just above the positivity threshold. This is consistent with 411 
previous reports showing that significant immunological differences exist between BTV15 and other 412 
BTV serotypes and that monoclonal antibodies raised against BTV1 VP7 failed to react with BTV15 413 
VP7 [37]. When assessing diagnostic tools aiming at non-serotype specific detection, it would be 414 
therefore advisable to include distantly related strains in the test panel to cover most of the genetic 415 
variability displayed by BTV proteins.   416 
Vandenbussche et al. suggested to use the ID Vet cELISA kit with a cut off of 66 PN instead of 35 for 417 
BTV8, as recommended by the manufacturer, to achieve optimal accuracy for both screening and 418 
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diagnostic [38]. Taking into account this suggestion, all of the three calves would have been 419 
considered as seropositive by day 21 post infection with BTV15. 420 
Conclusion  421 
Unlike the European BTV8, known for its increased virulence in bovine, BTV1 and BTV15 have been 422 
associated with subclinical or very mild disease in this species. Numerous factors are known to 423 
influence the severity of BT in individual ruminants; nutritional status, immune status and age, breed, 424 
environmental stresses such as high temperature and ultraviolet radiation [39]. . In this study, the 425 
accidental co-infection with BTV1 and BTV15 and the obtained severe clinical outcome underlined 426 
the potential higher pathogenicity of a co-infection.  427 
The main objective of this study was to observe the outcomes of a superinfection in calves previously 428 
immunized with the European BTV8. BTV1 or BTV15 RNA detection in superinfected animals was 429 
not different whether BTV8 immunization was acquired through vaccination and challenges or 430 
challenges alone. Furthermore, a low cross neutralization was measured between BTV8 and BTV1, 431 
and between BTV8 and BTV15. Taken all together in the context of the European BT epidemiological 432 
situation, the results could suggest that an infection or a vaccination with the European BTV8 strain 433 
would not efficiently protect the bovines from a superinfection with the BTV1 or BTV15 strains used 434 
in the study. 435 
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 577 
Figures 578 
Figure 1. Neutralising antibodies and viral RNA detection following BTV8 challenges and 579 
BTV1/BTV15 superinfection. 580 
(A) Mean neutralising antibodies titres and mean copy number of VP2 cDNA are shown for 581 
vaccinated (V) and non-vaccinated (NV) calves, after vaccinations and challenges with BTV8 and 582 
BTV1/BTV15 superinfection. Standard deviation is shown as error bars. The two vaccine injections 583 
are represented as arrows followed by Vacc1 and Vacc2 respectively. Infectious challenges are 584 
represented as arrow labelled with the corresponding serotypes. * above braces: time period with 585 
neutralising Abs titre of V group significantly higher than NV group; P<0.05. (B) Focus on the 586 
BTV1/BTV15 superinfection experiment.  587 
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Figure 2. Serology, RNA detection and cross neutralization results following single infections 588 
with BTV1, BTV15 and BTV8. 589 
(A) Results of RTqPCR and SNT in V and NV groups of calves, after BTV1 and BTV15 single 590 
infection challenges compared with BTV8 first challenge in NV group. Dashed lines represent SNT 591 
results. (B) cELISA % of negativity following BTV1 and BTV15 single infection, BTV8 vaccination 592 
in V group and first BTV8 challenge in NV group. Dotted line represents positivity threshold, with % 593 
of negativity <35 considered as positive. (C) Cross neutralization results, with BTV1, BTV8 and 594 
BTV15 compared to the respective heterologous immune serum. Results are expressed as a percentage 595 
of the highest homologous neutralization titre. *: P<0.05; ** P<0.01. 596 
Figure 3. BTV RNA detection in organs. 597 
(A) BTV1, BTV8 and BTV15 detection in organs following BTV1/BTV15 superinfection. (B) BTV1 598 
and BTV15 detection in organs following single infections. Results are expressed as Log10 copy 599 
number/100 mg of tissue. Mesent. LN: Mesenteric lymph node. Prescap. LN: Prescapular lymph node. 600 
Figure 4. In vitro growth kinetics of BTV1, 8 and 15 on VERO and BPAEC cells. 601 
VERO cells (A) and BPAEC (B) were infected at a multiplicity of infection (M.O.I.) of 0.05 and 602 
supernatants collected at 8, 24, 48, and 120 h post infection (hpi). Viruses were the same as used for 603 
single infection (BTV1 and BTV15) and BTV8 was the same as in the BTV8 successive infection 604 
experiment. Supernatants were then titrated on VERO cells by end-point dilution and the virus titres 605 
expressed as log10 TCID50/ml. Three different assays were performed independently, each time 606 
involving the three serotypes, tested on the different cell lines. Standard deviations are displayed as 607 
error bars. 608 
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BTV group specific anti-VP7 antibodies, after vaccination against BTV8 and BTV8 challenges, 611 
for non-vaccinated, control and vaccinated calves 612 
BTV group specific anti-VP7 antibodies as the % of negativity. Dashed line represents the cut off 613 
value. A % of negativity under the cut off (35 %) is considered positive. NV: non vaccinated; V: 614 
vaccinated. The two vaccine injections are represented as arrows labelled Vac1 and Vac2 respectively, 615 
and first and second BTV8 challenges are represented as green arrows. Standard deviations are 616 
represented as error bars. 617 
 618 
Additional file 2.csv 619 
Cumulative clinical scores 620 
Cumulative clinical scores after the first BTV8 challenge in NV and V animals, BTV1/BTV15 621 
superinfection and BTV1 and BTV15 single infections. Sd: Standard deviation. 622 
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